Galderma opens new U.S. and Latin America headquarters in Miami

• Galderma officially opens its U.S. and Latin America headquarters in Miami, Florida, positioning the company at the center of a fast-growing market for Dermatological Skincare and Injectable Aesthetics.
• The opening underscores the strategic importance of the United States, Galderma's largest market, and builds on the company's previously announced commitment to invest more than 650 million USD on U.S. manufacturing through 2030.
• The headquarters brings together key members of Galderma's leadership team in Miami, strengthening collaboration.
• Galderma expects to employ approximately 200 colleagues in Miami over time, reflecting its long-term commitment to the region.

MIAMI, Aug. 24, 2026 /PRNewswire/ -- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the official opening of its U.S. and Latin America headquarters in Miami, establishing a new operational center for its U.S. business. The opening reflects the company's continued investment in the United States and marks another milestone in Galderma's long-term growth strategy.

The new headquarters brings key members of Galderma's leadership team together, accelerating decision-making, strengthening collaboration, and supporting continued growth across its U.S. and Latin America operations. The United States is Galderma's largest market, reflecting strong demand across its Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology categories. In the first half of 2026, Galderma recorded 3.134 billion USD in net sales in H1 2026, growing 24.6% year-on-year at constant currency.

Located in Miami's Brickell district, the headquarters will serve as the primary base for U.S. commercial roles across Dermatological Skincare and selected functional teams. Galderma also plans to host healthcare professionals at the facility, which features a dedicated injection room designed to support hands-on training, educational programs, and the development of educational materials. The space also includes an installation modeled on the ALASTIN Signature Practice experience, giving visiting professionals a firsthand look at how regenerative, peri-procedural skincare integrates into everyday patient care. Complementing this focus on professional education, Galderma has hosted more than 1,000 Galderma Aesthetic Injector Network (GAIN) training events in the U.S. to date in 2026, serving around 5,000 participants.

Miami was selected for its strong position as a premium market for dermatological skincare, aesthetics, and consumer health, aligning closely with Galderma's U.S. ambitions. The city's deep pool of business and scientific talent has enabled Galderma to make several key hires in consumer skincare, aesthetics, and digitally native commercial roles. Miami also offers robust connectivity across the U.S. and Latin America, making it well positioned to support Galderma's expanding business and to strengthen relationships with healthcare professionals, partners, and customers across both regions.

"As our largest market, the United States is central to Galderma's long-term growth. This investment reflects our confidence in its continued expansion and our ambition to build Galderma into a dermatology powerhouse, scientifically, commercially, and operationally. By bringing key members of our U.S. and Latin America leadership teams together in Miami, we are creating a strategic hub that strengthens collaboration and enables us to execute our Integrated Dermatology Strategy with even greater impact."

FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA

Investing for long-term growth in the U.S.

Galderma's new Miami headquarters is one component of the company's broader U.S. growth strategy. It complements the company's previously announced commitment to invest more than 650 million USD in U.S. manufacturing through 2030, alongside continued investments across research, education and training, operations, and commercial activities.

Leadership across attractive and fast-growing segments of dermatology has continued to drive Galderma's momentum, with the company reporting record global net sales of 5.207 USD billion in 2025. Its science-based portfolio spans Injectable Aesthetics, including leading brands such as Dysport^®, Restylane^®, and Sculptra^®; Dermatological Skincare, including Cetaphil^® and Alastin^®; and Therapeutic Dermatology, including Nemluvio^®, reflecting its breadth across the full spectrum of dermatology.

"Our new headquarters reflects how we want to work – bringing together expertise from across the business so teams can collaborate more effectively and move with greater agility. It strengthens our ability to execute on our strategy while supporting Galderma's continued growth in the United States."

SILVINA NORDENSTOHL
HEAD OF U.S. — AD INTERIM
GALDERMA

A space that reflects Galderma's values

The new headquarters was intentionally designed to foster teamwork, creativity, and employee wellbeing by bringing key members of Galderma's U.S. and Latin American teams together under one roof. Its interior draws inspiration from Japandi design principles, combining Scandinavian functionality with Japanese minimalism to create a calm, modern workplace that reflects Galderma's focus on purposeful innovation and scientific excellence.

About Galderma

Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that spans the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we're in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com 

For further information:

SOURCE Galderma